CASE DISCUSSION
Radiation Oncology: Understanding Emerging Advancement
Presented India by Dr. Pradeep Kumar KarumanchiViews
3,891
Credit Points
Learning Hours
CPD Points
CME Points
Courses Completed
Case Description
Emerging advances in Radiation Oncology aims at defining the current role and future potential of technological, medical physics and molecular/biological innovations for their incorporation into routine clinical practice in radiation oncology. Dr Pradeep will help us understand where advances in...
Case Summary
- Radiation oncology utilizes high-energy radiations, such as photons, protons, and electrons, to treat cancer. It can be categorized into teletherapy (external beam), stereotactic radiotherapy (focused, high-dose), and brachytherapy (internal radioactive source). Teletherapy techniques include 3D-CRT, IMRT, IGRT, and adaptive radiation therapy.
Speaker Profile
Dr. Pradeep Kumar Karumanchi
Consultant Radiation Oncologist, Yashoda Hospitals, HyderabadDr. Pradeep Kumar Karumanchi is one of the best Radiation Oncologists in Hyderabad with expertise in treating all types of cancers. He has been trained in High Precision Radiotherapy Techniques like Cyberknife, Tomotherapy, SRS, SBRT, VMAT, IGRT, IMRT, TBI and HDR Brachytherapy. He has been trained at prestigious Institutes in India and abroad. He also received specialty training in Urologic Oncology and GI Oncology from world renowned Memorial Sloan-Kettering Cancer Center(MSKCC), USA. He received training in Thoracic Oncology from Univ. of Michigan, USA and Precision Oncology from Univ. de Geneve, Switzerland. He is actively involved in clinical research and has scientific publications in International journals. He believes in the ‘Quality-of-LIfe’ concept and treats patients with special consideration in improving their quality of life. He has special interest in Radiomics and Radio-genomics with Active Precision Oncology Research in the imaging space and the usage of artificial intelligence in prognosticating and predicting the outcomes and side-effects of cancer.
Disclosures
Assimilate by Medvarsity requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.